journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/28099369/the-cessation-of-anti-pd-1-antibodies-of-complete-responders-in-metastatic-melanoma
#1
Rahul Ladwa, Victoria Atkinson
The optimal duration of PD-1 antibodies for metastatic melanoma is unknown. In previous trials, there has been the potential to cease therapy if the patient achieves a complete response (CR). We aimed to assess the outcomes of patients who had ceased anti-PD-1 antibodies in this setting. A retrospective review was carried out of CR to PD-1-based therapy across two institutions. Patients were from the Pembrolizumab Named Patient Program (PEM NPP), Nivolumab monotherapy (NIVO), and reimbursed Pembrolizumab (r PEM)...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099368/recurrence-behavior-in-early-stage-cutaneous-melanoma-pattern-timing-survival-and-influencing-factors
#2
Faruk Tas, Kayhan Erturk
Nearly one-third of all melanoma patients will experience disease recurrence and the majority of the relapses eventually develop metastatic disease as a consequence of disease progression in the early-stage melanoma patients. Although the factors that predict the recurrence have already been described, very few numbers of studies have investigated the natural recurrence history of melanoma. In this retrospective study, we analyzed the time until recurrence along with the patterns and outcomes of the recurrences; thus, we aimed to understand the possible factors that might influence the recurrence course in early-stage cutaneous melanoma at the first relapse...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099367/antiphospholipid-syndrome-associated-with-combined-immune-checkpoint-inhibitor-therapy
#3
Arjun Gupta, Udayan Shah, Htet Khine, Travis Vandergriff, Thomas Froehlich
No abstract text is available yet for this article.
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099366/does-the-distribution-pattern-of-brain-metastases-during-braf-inhibitor-therapy-reflect-phenotype-switching
#4
Silvia A Haueis, Pascale Kränzlin, Joanna Mangana, Phil F Cheng, Mirjana Urosevic-Maiwald, Ralph P Braun, Mitchell P Levesque, Reinhard Dummer, Simone M Goldinger
Brain metastases (brain mets) are frequent in metastatic melanoma patients. The aim of this study was to investigate the morphology and progression pattern of brain mets in melanoma patients treated with BRAF inhibitors (BRAFi) compared with patients who did not receive targeted therapy (BRAFi group and control group). The number and size of brain mets were compared between a baseline and a comparative MRI at progression. The number of brain mets was grouped into seven number classes (N=1-4, N=5-10, N=11-20, N=21-30, N=31-40, N=41-50, and N>50) and its difference was reported as the change of class that occurred...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28099365/melanoma-during-pregnancy-a-report-of-60-pregnancies-complicated-by-melanoma
#5
Jorine de Haan, Christianne A Lok, Christianne J de Groot, Marianne B Crijns, Kristel Van Calsteren, Karina Dahl Steffensen, Michael J Halaska, Sevilay Altintas, Ingrid A Boere, Robert Fruscio, Wojciech Kolawa, Petronella O Witteveen, Frédéric Amant
The management of melanoma during pregnancy is challenging as maternal benefits and fetal risks need to be balanced. Here, we present an overview of the incidence, the demographic and clinical characteristics and the treatment modalities used. After analysis of obstetric, fetal and maternal outcome, recommendations for clinical practice are provided. From the 'International Network on Cancer, Infertility and Pregnancy' database, pregnant patients with melanoma were identified and analysed. Sixty pregnancies were eligible for analysis...
January 17, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28079609/mesenchymal-stem-cells-induce-epithelial-mesenchymal-transition-in-melanoma-by-paracrine-secretion-of-transforming-growth-factor-%C3%AE
#6
Chuan Lv, Haiying Dai, Mengyan Sun, Hui Zhao, Kai Wu, Ji Zhu, Yuchong Wang, Xian Cao, Zhaofan Xia, Chunyu Xue
Mesenchymal stem cells (MSCs) are considered for potential use as an ideal vehicle to efficiently deliver therapeutic agents in treatment against cancers including melanoma. However, emerging evidence indicates that MSCs promote tumor growth and progression. Therefore, a comprehensive understanding of the role of MSCs is very important to evaluate the MSCs-based therapy in melanoma. B16 melanoma cells treated by MSC conditioned medium (CM), showed significantly enhanced migration and invasion, which was also confirmed in a lung metastasis mice model in vivo...
January 5, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28060055/genetic-counselling-and-high-penetrance-susceptibility-gene-analysis-reveal-the-novel-cdkn2a-p-d84v-c-251a-t-mutation-in-melanoma-prone-families-from-italy
#7
Riccardo G Borroni, Ausilia M Manganoni, Sara Grassi, Maurizia Grasso, Marta Diegoli, Carmela Giorgianni, Valentina Favalli, Laura Pavoni, Maddalena Cespa, Eloisa Arbustini
Genetic susceptibility to primary cutaneous melanoma (PCM) may account for up to 12% of PCMs, presenting as the familial atypical mole/multiple melanoma syndrome (FAMMM), an autosomal dominant condition with incomplete penetrance and variable expressivity, characterized by PCM in at least two relatives and/or more than one PCMs in the same patient. To identify individuals at high genetic risk of PCM, from 1 January 2012 to 31 December 2015, we offered genetic counselling and molecular analysis of the two high-penetrance FAMMM susceptibility genes, cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase 4 (CDK4), to 92 consecutive, unrelated patients with FAMMM...
January 4, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28030434/exhaustive-pathologic-work-up-in-sentinel-lymph-node-biopsy-for-melanoma-is-it-necessary
#8
Leonardo S Lino-Silva, Ana L Castillo-Medina, Rosa A Salcedo-Hernández, Leticia García-Pérez
The objective of this study is to determine whether a less exhaustive pathologic work-up to detect melanoma metastasis is clinically useful and does not affect patient prognosis. The success and evolution of the sentinel lymph node (SLN) depends on histological techniques. Several exhaustive protocols of SLN analysis have been published, but are time and cost consuming, with slight increases in the rates of metastasis detection. From 281 patients with SLN biopsy, each SLN was sectioned every 2 mm and from each paraffin block, 2-3 histological sections were evaluated...
December 27, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27997431/attenuation-of-genome-wide-5-methylcytosine-level-is-an-epigenetic-feature-of-cutaneous-malignant-melanomas
#9
Goran Micevic, Nicholas Theodosakis, Janis M Taube, Marcus W Bosenberg, Nemanja Rodić
Epigenetic modification of DNA, namely covalent changes of cytosine residues, plays a key role in the maintenance of inactive chromatin regions, both in health and in disease. In the vast majority of malignant melanomas, the most notable known epigenetic abnormality is the attenuation of 5-hydroxymethylcytosine (5-hmC) residues. However, it remains unknown whether a decrease in 5-hmC represents a primary defect of melanoma cancer epigenome or whether it is secondary to the loss of 5-methylcytosine (5-mC), a chemical substrate for 5-hmC...
December 16, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27977496/new-onset-third-degree-atrioventricular-block-because-of-autoimmune-induced-myositis-under-treatment-with-anti-programmed-cell-death-1-nivolumab-for-metastatic-melanoma
#10
Juliane Behling, Joachim Kaes, Thomas Münzel, Stephan Grabbe, Carmen Loquai
There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic melanoma. Anti-programmed cell death-1-blocking antibodies are known to cause immune-related adverse events. Physicians should be aware of common and rare side effects and pay attention to new ones. We therefore report a severe and life-threatening side effect of anti-programmed cell death-1 immunotherapy with nivolumab that has not been previously reported: the development of a third-degree atrioventricular block...
December 13, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27926588/incidence-trends-and-clinical-pathological-characteristics-of-invasive-cutaneous-melanoma-from-1980-to-2010-in-the-canton-of-zurich-switzerland
#11
Remo Minini, Sabine Rohrmann, Ralph Braun, Dimitri Korol, Silvia Dehler
The aims of this paper are to describe the incidence trends of invasive cutaneous melanoma in the Canton of Zurich and to evaluate clinical and pathological factors such as cancer subtype, localization, age and Breslow thickness. A retrospective analysis was carried out with data from the population-based Cancer Registry of Zurich and Zug located in Zurich. A total of 8469 cases in 8034 different patients of invasive cutaneous melanoma were registered for the period 1980-2010 in the Canton of Zurich. Incidence trends were age standardized to the European standard population...
December 6, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27926587/anti-programmed-cell-death-protein-1-tolerance-and-efficacy-after-ipilimumab-immunotherapy-observational-study-of-39-patients
#12
Reyhan Amode, Barouyr Baroudjian, Anita Kowal, Majdi Jebali, Clara Allayous, Martine Bagot, Nika Madjlessi, Jennifer Roux, Manuelle Viguier, Nicole Basset Seguin, Raphaël Porcher, Cécile Pagès, Céleste Lebbé
In patients with ipilimumab (IPI)-refractory melanoma, the anti-programmed cell death proteins 1 (PD1s) nivolumab (NIV) and pembrolizumab (PEM) are considered to be a new standard of treatment. Few data are available on anti-PD1 safety in patients who develop IPI-related severe adverse events (AEs) (grade≥3). The aim of this study was to compare the anti-PD1 safety and efficacy in patients with previous severe toxicity to IPI versus in those showing moderate and no previous IPI-related AEs. This single institution-based observational study included all patients treated with anti-PD1 (PEM or NIV) and previously treated with IPI for unresectable stage III or IV melanoma...
December 6, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27824739/effect-of-the-lymphocyte-to-monocyte-ratio-on-the-clinical-outcome-of-chemotherapy-administration-in-advanced-melanoma-patients
#13
Alexey A Leontovich, Roxana S Dronca, Wendy K Nevala, Michael A Thompson, Lisa A Kottschade, Leonid V Ivanov, Svetomir N Markovic
Skin cancer affects more individuals in the USA than any other malignancy and malignant melanoma is particularly deadly because of its metastatic potential. Melanoma has been recognized as one of the most immunogenic malignancies; therefore, understanding the mechanisms of tumor-immune interaction is key for developing more efficient treatments. As the tumor microenvironment shows an immunosuppressive action, immunotherapeutic agents promoting endogenous immune response to cancer have been tested (interleukin-2, anticytotoxic-T-lymphocyte-associated antigen 4, and antiprogrammed cell death protein 1 monoclonal antibodies) as well as combinations of cytotoxic chemotherapy agents and inhibitors of angiogenesis (taxol/carboplatin/avastin)...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27792059/vitamin-d-receptor-immunohistochemistry-variability-in-sun-exposed-and-non-sun-exposed-melanomas
#14
Giovanni Paolino, Chiara Panetta, Carlo Cota, Dario Didona, Elisa Moliterni, Cinzia Di Mattia, Gaetano De Vita, Ugo Bottoni, Pietro Donati, Stefano Calvieri
Ultraviolet rays are one of the leading factors in the development of melanoma (MM); however, ultraviolet rays seem not to play a role in non-sun-exposed MM, where systemic immunosuppression, anatomical, and physiological features may contribute toward the development of the malignancy. Our aim was to evaluate vitamin D receptor (VDR) expression in shield-site melanoma (ST-MM) and non-shield-site melanoma (NST-MM) to find features that could explain the different biological behavior of MM according to the area of onset...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27792058/clinical-features-and-response-to-systemic-therapy-in-a-historical-cohort-of-advanced-or-unresectable-mucosal-melanoma
#15
Alexander N Shoushtari, Mark J Bluth, Debra A Goldman, Christiana Bitas, Robert A Lefkowitz, Michael A Postow, Rodrigo R Munhoz, Gauri Buchar, Robert H Hester, Jacqueline A Romero, Laura J Fitzpatrick, Martin R Weiser, Katherine S Panageas, Jedd D Wolchok, Paul B Chapman, Richard D Carvajal
There are very few data available regarding the pattern of first metastases in resected mucosal melanomas (MMs) as well as the response of advanced MM to cytotoxic therapy. A retrospective, single-institution cohort was assembled of all patients with advanced/unresectable MM between 1995 and 2012 who had received systemic therapy with available imaging (N=81). Responses to first-line and second-line systemic therapy were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The relationship between response, overall survival, and clinical covariates was investigated using Cox proportional hazards regression...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27776018/inhibitor-of-vasculogenic-mimicry-restores-sensitivity-of-resistant-melanoma-cells-to-dna-damaging-agents
#16
Amalia Vartanian, Maria Baryshnikova, Olga Burova, Dariya Afanasyeva, Vsevolod Misyurin, Alexander Belyаvsky, Zoya Shprakh
The increasing incidence of melanoma makes this cancer an important public health problem. Therapeutic resistance is still a major obstacle to the therapy of patients with metastatic melanomas. The aim of this study was to develop the melanoma cell line resistant to DNA-alkylating agents and to elucidate the mechanisms involved in acquired drug resistance. We established a unique melanoma subline Mel MeR resistant to DNA-alkylating drug aranoza by continuous stepwise selection of the Mel Me/WT cell line with increasing concentrations of this drug...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27768639/high-cytotoxic-t-lymphocyte-associated-antigen-4-and-phospho-akt-expression-in-tumor-samples-predicts-poor-clinical-outcomes-in-ipilimumab-treated-melanoma-patients
#17
Nitin Chakravarti, Doina Ivan, Van A Trinh, Isabella C Glitza, Jonathan L Curry, Carlos Torres-Cabala, Michael T Tetzlaff, Roland L Bassett, Victor G Prieto, Wen-Jen Hwu
Ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is the first immune checkpoint inhibitor approved for the treatment of unresectable melanoma on the basis of its overall survival (OS) benefit. However, ipilimumab is associated with significant immune-related adverse events. We hypothesized that biomarker exploration of pretreatment tumor samples and correlation with clinical outcome would enable patient selection with an increased benefit/risk ratio for ipilimumab therapy...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27764061/inflammatory-regulation-of-stem-like-cells-in-melanoma
#18
Ming-Sheng Lim, Jiang Huai Wang, Derek G Power, H Paul Redmond
The link between inflammation, immunity and cancer is well established. In the last decade, there has been considerable excitement over cancer stem cells, believed to be a subset of tumour cells responsible for their initiation, propagation and resistance to conventional chemoradiotherapy. In this review, we discuss the characterization of cancer stem cells and describe their modulation by inflammation with a focus on melanoma.
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27764060/adjuvant-external-beam-radiotherapy-after-therapeutic-groin-lymphadenectomy-for-patients-with-melanoma-a-dosimetric-comparison-of-three-dimensional-conformal-and-intensity-modulated-radiotherapy-techniques
#19
Gerard Adams, Matthew Foote, Simon Brown, Bryan Burmeister
Radiotherapy after lymph node dissection is recommended in high-risk melanoma cases. The aim of this study is to assess whether intensity-modulated radiotherapy (IMRT) offers advantages over three-dimensional conformal radiotherapy (3DCRT) in the groin nodal basin. Fifteen consecutively treated patients (5 3DCRT and 10 IMRT) were selected. Optimized theoretical plans using the other modality were created - enabling direct comparisons of 3DCRT and IMRT. Target volume and organs at risk constraints were assessed as achieved or as having minor (≤5%) or major (>5%) deviations...
February 2017: Melanoma Research
https://www.readbyqxmd.com/read/27759578/tumor-free-osteosclerotic-lesions-in-patients-treated-for-metastatic-melanoma-using-braf-inhibitors
#20
Lea Bottlaender, Marie Perier-Muzet, Véronique Lapras, Luc Thomas, Stephane Dalle
BRAF inhibitors (vemurafenib and dabrafenib) are commonly prescribed in BRAF-mutant metastatic melanoma and allow improvement of the overall survival and progression-free survival. They are, however, accompanied by many adverse effects which mainly affect the skin. We observed on computed tomographic scans in three different patients after 3 months of treatment, the onset of osteosclerotic lesions. In parallel, the computed tomographic scans showed a significant reduction in all of the previously identified metastases in all patients...
February 2017: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"